cymbalta - Drivetime Radio

ePAPER READ

DOWNLOAD ePAPER

drivetimeradio.com.au

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

Table 4 Summary of Primary Efficacy in acute placebo-controlled GAD studiesStudy/durationTreatment Group N Baseline Endpoint LSMeanChangep-valuevsplaceboHMBR Duloxetine 60 mg QD 165 25.05 12.32 -12.8

Product Information Sandrena 0.1% gel - Aspen Pharmacare Australia

PRODUCT INFORMATION PRISTIQ ... - Drivetime Radio

MINIRIN® Nasal Spray - DriveTime Radio Home Page

MINIRIN Melt - DriveTime Radio Home Page

Table 4 Summary of Primary Efficacy in acute placebo-controlled GAD studiesStudy/durationTreatment Group N Baseline Endpoint LSMeanChangep-valuevsplaceboHMBR Duloxetine 60 mg QD 165 25.05 12.32 -12.8

Page 1 and 2: CYMBALTA ®(duloxetine hydrochlorid
Page 3 and 4: metabolites circulating in plasma a
Page 5 and 6: evaluation of efficacy of duloxetin
Page 7: diary, Brief Pain Inventory Severit
Page 13 and 14: transaminase elevations resulted in
Page 15 and 16: myocardial infarction or unstable h
Page 17 and 18: judgement, thinking or motor skills
Page 19 and 20: amounts of alcohol.Drugs Metabolise
Page 21 and 22: Nausea (duloxetine 1.3%, placebo 0.
Page 23 and 24: abcdefghIjkAlso includes abdominal
Page 25 and 26: Gastrointestinal DisordersCommon: d
Page 27 and 28: Eye disordersVery rare: Glaucoma.He
Page 29 and 30: ecommended that the dose be tapered

cymbalta - Drivetime Radio

Create successful ePaper yourself

Delete template?

Save as template?